Abbott Labs meets Q2 earnings estimates, sets FY 2025 EPS guidance between $5.10-$5.20.

Abbott Laboratories reported second-quarter earnings of $1.26 per share, meeting estimates, with revenue at $11.14 billion. Park National Corp reduced its holdings by 9,998 shares, now owning 227,790 shares, while Trust Co of the South increased its holdings by 468 shares. LVM Capital Management also reduced its holdings. Abbott has set FY 2025 EPS guidance at 5.100-5.200 and Q3 2025 EPS guidance at 1.280-1.320.